MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study

Abstract

Background In Western countries, ovarian cancer (OC) still represents the leading cause of gynecological cancer-related deaths, despite the remarkable gains in therapeutical options. Novel biomarkers of early diagnosis, prognosis definition and prediction of treatment outcomes are of pivotal importance. Prior studies have shown the potentials of micro-ribonucleic acids (miRNAs) as biomarkers for OC and other cancers. Methods We focused on the prognostic and/or predictive potential of miRNAs in OC by conducting a comprehensive array profiling of miRNA expression levels in ovarian tissue samples from 17 non-neoplastic controls, and 60 tumor samples from OC patients treated at the Regina Elena National Cancer Institute (IRE). A set of 54 miRNAs with differential expression in tumor versus normal samples (T/N-deregulated) was identified in the IRE cohort and validated against data from the Cancer Genoma Atlas (TCGA) related to 563 OC patients and 8 non-neoplastic controls. The prognostic/predictive role of the selected 54 biomarkers was tested in reference to survival endpoints and platinum resistance (P-res). Results In the IRE cohort, downregulation of the 2 miRNA-signature including miR-99a-5p and miR-320a held a negative prognostic relevance, while upregulation of miR-224-5p was predictive of less favorable event free survival (EFS) and P-res. Data from the TCGA showed that downregulation of 5 miRNAs, i.e., miR-150, miR-30d, miR-342, miR-424, and miR-502, was associated with more favorable EFS and overall survival outcomes, while miR-200a upregulation was predictive of P-res. The 9 miRNAs globally identified were all included into a single biologic signature, which was tested in enrichment analysis using predicted/validated miRNA target genes, followed by network representation of the miRNA-mRNA interactions. Conclusions Specific dysregulated microRNA sets in tumor tissue showed predictive/prognostic value in OC, and resulted in a promising biological signature for this disease.

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration

“…Based on their mechanism of action, quantifying the relative miRNA deregulation reflects the tumor’s nature beyond its genomic and transcriptomic level, providing important insights into the altered cellular functions that are currently predominantly active. Overall, the available data confirm the multifaceted potential of these small molecules in BC, consistent with findings in other cancers [ 74 , 75 ].…”

A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview

“…Based on fatality, OCCC (ovarian clear cell carcinoma) is the second most prevalent kind of ovarian cancer, responsible for approximately 10-13 percent of all women diagnosed with the disease. Ovarian clear cell carcinoma was initially thought to be connected with endometriosis, the most likely antecedent lesion for the condition [19]; however, this hypothesis must be proven [24]. It begins in the epithelial layer of the ovary, which is the lining of the ovary, just like the majority of ovarian malignancies.…”

“…The role of microRNAs (miRNAs) in chemoresistance, metastatic potentials, EMT, and the control of CSCs has been demonstrated in OC research [17,18]. Although only a few researchers have done a broad miRNA profiling in ovarian cancer intending to discover and validate miRNA expression biological fingerprints that are more than only prognostic and/or predictive, we believe this is a significant step forward [19].…”

Intratumor microbiome in cancer progression: current developments, challenges and future trends

“…Cancers have a dismal prognosis, and outcomes have improved little with modern [ 161 – 164 ] and traditional [ 59 , 165 , 166 ] therapeutic strategies. Apart from tumor cell-intrinsic mechanisms, discovering the intratumor microbiome and elucidating host-microbe interactions present opportunities for intervention [ 1 , 2 , 167 ].…”